Original Article
Prediction of Mortality in Patients with Cystic Fibrosis
N Engl J Med 1992; 326:1187-1191April 30, 1992
- Abstract
- Abstract
Background.
The majority of patients with cystic fibrosis die in early adulthood of lung disease. Lung transplantation is a treatment option for patients with advanced pulmonary disease, although the waiting period for organs may be as long as two years. Our purpose was to determine whether the risk of death due to respiratory failure could be predicted one or two years in advance on the basis of pulmonary function, blood gas levels, and nutritional status.
Methods.
The study cohort consisted of 673 patients followed between 1977 and 1989. In each patient, pulmonary function, blood gas levels, nutritional status, and vital status were assessed between 1977 and 1987. Cox proportional-hazards regression analysis was used to compute the relative risk of death within one or two years after particular measurements. The effects of age and sex on mortality were also included in the analysis.
Results.
One hundred ninety patients (28 percent) died during the study period. Overall, patients with a forced expiratory volume in one second (FEV1)less than 30 percent of the predicted value, a partial pressure of arterial oxygen below 55 mm Hg, or a partial pressure of arterial carbon dioxide above 50 mm Hg had two-year mortality rates above 50 percent. Among the laboratory measurements, the FEV1 was the most significant predictor of mortality, but age and sex were also significant in predicting risk. After adjustment for age and sex, the relative risk of death within two years was 2.0 (95 percent confidence interval, 1.9 to 2.2) for each decrement in the FEV1 of 10 percent below the predicted value. Among patients with the same FEV1, the relative risk of death was 2.0 (95 percent confidence interval, 1.5 to 2.6) in patients 10 years younger than other patients, and 2.2 (1.6 to 3.1) in female patients as compared with male patients.
Conclusions.
Patients with cystic fibrosis should be considered candidates for lung transplantation when the FEV1 falls below 30 percent of the predicted value. Female patients and younger patients may need to be considered for transplantation at an earlier stage. (N Engl J Med 1992;326:1187–91.)
Article Activity
- Article
DURING the past three decades the life expectancy of patients with cystic fibrosis has improved dramatically, but the majority still die in early adulthood from respiratory failure associated with pulmonary hypertension and cor pulmonale.1 In patients with this disease, it is important that the prognosis be assessed so that the physician may intensify medical therapy, consider new approaches to treatment, or refer the patient for lung transplantation. At present, double-lung or heart-lung transplantation is the only definitive treatment for patients with advanced cystic fibrosis. The results of lung transplantation in adults2 and children3 with this disorder have been encouraging in terms of survival and associated improvement in lung function2 , 3 and the quality of life.4
It has been suggested that lung transplantation should be considered for patients with cystic fibrosis whose quality of life is severely impaired and whose life expectancy is less than two years.5 Therefore, lung transplantation should be considered about two years before operation, in view of the scarcity of suitable donor organs and the need to determine the suitability of the potential recipient and to initiate a rehabilitation program.5 Although several previous reports6 7 8 9 10 11 12 13 have assessed the long-term outcome of patients with cystic fibrosis, prognostic indicators of short-term survival are not available. In the present study, we retrospectively analyzed the clinical course of patients with cystic fibrosis in an attempt to predict their mortality rates at one and two years on the basis of lung function, blood gas measurements, and nutritional status.
Methods
Measurement of Variables
The study cohort consisted of 673 patients with cystic fibrosis who were followed at the Hospital for Sick Children, Toronto, between 1977 and 1989. The diagnosis was based on typical clinical findings or a family history of cystic fibrosis, together with an abnormal sweat chloride value.1 Since 1977, a broad range of clinic data have been recorded at diagnosis and at each clinic visit (every three months) and incorporated into a computerized data base.13 All patients over six years old undergo routine testing of pulmonary function at six-month intervals. Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were expressed as percentages of the normal predicted values for height and sex that have been established in our laboratory. Blood gas levels —the partial pressure of arterial oxygen (Pa02) and carbon dioxide (PaCO2) — were determined in "arterialized" blood samples.14 Height and weight percentiles and weight as a percentage of the ideal weight for height and sex (weight-for-height percentage) were computed15 with use of the standards of Tanner et al.16
All patients whose pulmonary function was evaluated at least once before the end of 1987 were included in the study, thus allowing at least two years of follow-up in all patients. Records of pulmonary function and growth measurements from the date nearest each birthday in the years 1977 to 1987 were collected for each patient, along with the date of death. The percentages of patients who died within one or two years of particular measurements were calculated according to pulmonary-function variables, sex, and age. Since all the above measurements are performed routinely in patients in our clinic, it was deemed unnecessary to obtain informed consent from the patients studied or approval for the project from the Human Ethics Committee of the hospital.
Statistical Analysis
To assess the relative value of the variables in predicting death one or two years in advance, whether as independent variables or in combination with others, Cox proportional-hazards regression analysis was performed with a FORTRAN program that incorporated time-dependent covariates.17 For the purpose of this survival analysis, each patient was considered to have entered the study on the date of the first pulmonary-function test conducted in the study period. At the time of each death, values for covariates measured one or two years earlier in the patient were incorporated into a comparison, with similarly lagged values for the patients surviving at that point. The covariates included in the regression models included sex, age, FEV1, FVC, Pa02, PaCO2, and weight-for-height percentage. Regression-analysis models were produced for each covariate separately and for different combinations of pulmonary-function variables with age and sex. P values are two-tailed.
Results
One hundred ninety patients (80 of whom were male and 110 female), or 28 percent of the 673 patients with cystic fibrosis who were followed in our clinic and underwent pulmonary-function tests, died during the 13-year study period. We excluded 16 patients who died within one year of their first measurements in the study period and 29 who did not undergo testing at our hospital within two years of their death. Twelve percent of the remaining 145 patients died before the age of 11 years, 71 percent died between 12 and 23 years of age, and 17 percent died between 24 and 44 years of age. Two thirds of the patients who died before the age of 24 years were female, whereas only one third of those who died at an older age were female.
Figure 1Figure 1
One-Year and Two-Year Mortality Rates among Patients with Cystic Fibrosis, According to Pulmonary-Function Variable. shows the proportion of patients who died within 1 or 2 years, calculated from pooled annual measurements made during a 10-year period (1977 to 1987). The risk of death increased as all values for lung-function variables decreased. The approximate levels at which 50 percent of the patients died within two years of measurement were as follows: for FEV1, below 30 percent of the predicted value; for FVC, below 40 percent of the predicted value; for Pa02, below 55 mm Hg; and for PaCO2, above 50 mm Hg.A decrease in the weight-for-height percentage was also associated with an increase in the mortality rate: patients with values below 70 percent had a mortality rate above 50 percent within two years (Fig. 2Figure 2
One-Year and Two-Year Mortality Rates According to Weight-for-Height Percentage (Top Panel) and Two-Year Mortality According to Weight-for-Height Percentage and Age (Bottom Panel).). As a predictor of death, this variable (an indicator of nutritional status) had no more predictive value among the male patients than among the female patients. In the younger patients (6 to 17 years old) the weight-for-height percentage had less of an association with mortality within two years than in the older patients ( 18 to 44 years old) (Fig. 2).Proportional-hazards regression analysis confirmed that all the covariates except age were significant predictors of death (Table 1Table 1
Results of Regression Analysis with Models Using a Single Covariate.). We also assessed the relative importance of the covariates in multiple-variable models (Table 2Table 2
Results of Regression Analysis with Selected Models Using More than One Covariate.). Female sex was a significant predictor of a higher mortality rate in all models. The coefficient for age became negative and highly significant when FEV1 or FVC was included in the model, confirming that for given values of these measurements, younger patients were at higher risk of death within one or two years than older patients. Age was not a significant factor when Pa02 or PaCO2 was included in the model. The importance of age and sex was greatly reduced in the three-variable model that included weight-for-height percentage, reflecting the poorer nutritional status of female and older patients. Models with more than three predictor variables (data not shown) were also produced, but only age, sex, and FEV1 remained significant (P<0.001) in any of these models, suggesting that this three-variable model was the most useful. In particular, including Pa02 had a marginal effect (P = 0.03; relative risk per change of —5, 1.1), and including PaC02 (P = 0.8), FVC (P = 0.2), and weight-for-height percentage (P = 0.09) had no effect.The appropriateness of the model that included age, sex, and FEV1 was tested further. A model that included the year of death of each patient showed that calendar time was not a significant modifier (P = 0.7). The assumption of proportionality was tested for each covariate by including a time-dependent compound variable (covariate × log [time]). There was no evidence of nonproportionality. Separate models were fitted for male and female patients, but these models did not show within-sex variations of the effects of age and FEV1. A model was also produced from binary variables, to represent categories of FEV1, based on increments of 10 percent of the predicted value. This model showed an approximate doubling of risk with each reduction by 10 percent of the predicted value, similar to the much simpler model in which FEV1 served as a continuous variable.
Figure 3Figure 3
Two-Year Mortality Rate According to FEV1 and Sex (Top Panel) and Age (Bottom Panel). shows the effect of sex and age on the value of FEV1 for predicting death within two years, as in Figure 1. The 2-year mortality rate was calculated from pooled annual measurements for the 10-year period. The risk of death among female patients with FEV1 values between 20 and 30 percent was 56 percent, as compared with 38 percent among male patients. Likewise, children and adolescents had higher mortality rates for a given FEV1, value than did adults (Fig. 3). Thus, the two-year mortality rate among patients less than 18 years old who had FEV1, values that were 20 to 30 percent of the predicted value was 50 percent, as compared with 40 percent in patients 18 years old or older. The same pattern was seen when patients 6 to 17 years old were divided into those 6 to 11 years old and those 12 to 17 years old: the younger patients had higher mortality rates for a given FEV1 value.Discussion
Our study of patients with cystic fibrosis shows that severely impaired lung function is associated with poor short-term survival. Measurement of lung function should therefore form an integral part of the routine care of patients with cystic fibrosis. It provides a more objective assessment of the extent and progress of pulmonary disease in cystic fibrosis than do clinical scoring systems, which have been used in many previous studies to predict long-term survival.6 , 10
Our data show that patients with cystic fibrosis and values for FEV1 that are less than 30 percent of the predicted value have a 50 percent chance of dying within two years. In contrast, Huang et al.10 found that lung-function measurements were not good prognostic indicators, but these investigators examined only the 5-year survival of patients after the age of 18 years. In a previous study from three U.S. clinics, Wagener et al.18 reported that the mean survival of patients with an FEV1 less than 34 percent of the predicted value was 42 months, and only 26 months if carbon dioxide was retained (PaCO2 >40 mm Hg).
We found that the predictive value of FEV1 differed when we evaluated the patients according to subgroups. Female patients and patients younger than 18 years old, for example, had a less favorable prognosis for a given value of FEV1. Although investigators at some clinics have not observed a difference in survival between male and female patients,9 , 10 especially among older patients,10 national data6 , 8 , 11 , 19 , 20 indicate that male patients have remarkably better survival than female patients. In our study, the predictive value of age and sex decreased when nutritional status, as reflected by the weight-for-height percentage, was included in the analysis. This observation supports previous suggestions that the higher mortality among females may be related in part to a concomitant decrease in nutritional status.12 , 13 In our study, however, nutritional status was not a good predictor of two-year mortality, particularly in the younger patients.
Relative-risk estimates provide a quantitative method to describe the increased risk of death associated with each clinical characteristic. For example, at a given age and level of FEV1, female patients have a risk of death within two years more than double that of male patients. In patients of both sexes of any age, a decline in the FEV1 of 10 percent of the predicted value over a short time is associated with a twofold increase in risk, and of two patients of the same sex who have the same FEV1, level, the patient who is 10 years younger has a two-fold greater risk.
Although the FEV1 was found to be the most significant predictor of survival in our study, it should be pointed out that lung function m individual patients with cystic fibrosis can be influenced by several factors (e.g., sputum colonization with pseudomonal species, pancreatic function, and the presence of increased airway reactivity, atopy, and passive and active exposure to smoke).6 , 10 Furthermore, previous studies have shown that other factors not included in our Cox models, such as the mode of presentation,9 the extent of lung disease at diagnosis,9 treatment regimens,11 and psychosocial status,8 can influence survival.
In view of the patterns of survival presented, we believe that patients with FEV1 values less than 30 percent of the predicted value should be considered candidates for lung transplantation. Female patients and patients under 18 years old may need to be considered for lung transplantation at an earlier stage. It should be stressed, however, that the final decision to proceed with transplantation should be based on a comprehensive assessment of the patient's overall medical and psychosocial condition.5
There are considerable geographic differences in the survival of patients with cystic fibrosis6 7 8 9 10 11 12 13; patients in our clinic generally have a more favorable prognosis than their counterparts in other North American clinics and elsewhere.6 , 12 , 13 Can the results of our study therefore be extrapolated to experiences at other centers? During the past 20 years the survival rates of patients cared for at our clinic have plateaued, while the corresponding rates at other clinics in North America and in foreign countries have been steadily improving.6 7 8 9 10 11 , 20 The net result has been a more uniform survival among patients from different geographic locations. Thus, the median survival of patients attending 115 clinics for cystic fibrosis in the United States in 1990 was 27.6 years (Fitzsimmons S: personal communication), as compared with a median survival of 30.9 years among patients attending 32 specialized Canadian clinics between 1985 and 1989.19 Therefore, we think that our findings should enable care givers at other clinics to identify suitable candidates for lung transplantation. In this regard, patients with cystic fibrosis who were placed on an active waiting list at two British transplantation centers had values for FEV1 similar to those of patients who, on the basis of our study, would also be recommended as candidates.5
The principal barrier to lung transplantation is the limited availability of donors, although legislative initiatives21 , 22 and better techniques of lung preservation23 may improve the situation. In addition, lung transplantation remains an expensive procedure, although less expensive than the medical treatment of cystic fibrosis during its terminal phase.2 It is hoped that our data will make it possible to select the most appropriate patients for lung transplantation, and that meticulous attention to their medical and nutritional needs will optimize their likelihood of benefiting from this limited resource.
We are indebted to L. Green, S. Carpenter, L. Ellis, and the entire staff of the Cystic Fibrosis Clinic for their assistance in collecting the clinical data, and to J. Chay for assistance in the preparation of the manuscript.
Source Information
From the Pulmonary Division, Department of Pediatrics, Hospital for Sick Children, Toronto. Address reprint requests to Dr. Canny at the Pulmonary Division, Hospital for Sick Children, 555 University Ave., Toronto, ON M5G 1×8, Canada.
- References
References
1
MacLusky I, Levison H. Cystic fibrosis. In: Chernick V, ed. Disorders of the respiratory tract in children. 5th ed. Philadelphia: W.B. Saunders, 1990: 692–729.
2
Scott
CrossRef | Web of Science | Medline3
Whitehead
CrossRef | Web of Science | Medline4
Orenstein
CrossRef | Web of Science | Medline5
Whitehead
CrossRef | Web of Science | Medline6
Wood RE. Prognosis. In: Taussig LM, ed. Cystic fibrosis. New York: Thieme-Stratton, 1984:434–60.
7
Phelan
CrossRef | Web of Science | Medline8
Britton
CrossRef | Web of Science | Medline9
Hudson
CrossRef | Web of Science10
Huang
CrossRef | Web of Science | Medline11
British Pediatric Association Working Party on Cystic Fibrosis. Cystic fibrosis in the United Kingdom 1977–85; an improving picture . BMJ 1988;297:1599–602.
CrossRef | Web of Science12
Corey
CrossRef | Web of Science | Medline13
Corey ML. Longitudinal studies in cystic fibrosis. In: Sturgess JM, ed. Perspectives in cystic fibrosis: Proceedings of the Eighth International Congress on Cystic Fibrosis. Mississauga, Ont.: Imperial Press, 1980:24655.
14
Canny
Web of Science | Medline15
Moore
CrossRef | Web of Science16
Tanner
CrossRef | Web of Science | Medline17
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
18
Wagener JS, Taussig LM, Burrows B, Hernried L, Boat T. Comparison of lung function and survival patterns between cystic fibrosis and emphysema or chronic bronchitis patients. In: Sturgess JM, ed. Perspectives in cystic fibrosis: Proceedings of the Eighth International Congress on Cystic Fibrosis. Mississauga, Ont.: Imperial Press, 1980:236–45.
19
National report of the Canadian Data Registry, 1989. Toronto: Canadian Cystic Fibrosis Foundation, 1989.
20
Elborn
CrossRef | Web of Science | Medline21
Spital
Full Text | Web of Science | Medline22
Veatch
Full Text | Web of Science | Medline23
Hutter
CrossRef | Web of Science | Medline
- Citing Articles (172)
Citing Articles
1
Donald R VanDevanter, Michael W Konstan. (2012) Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation 2:2, 163-175
CrossRef2
Ariane Chryssostalis, Dominique Hubert, Joël Coste, Reem Kanaan, Pierre-Régis Burgel, Nadine Desmazes-Dufeu, Olivier Soubrane, Daniel Dusser, Philippe Sogni. (2011) Liver disease in adult patients with cystic fibrosis: A frequent and independent prognostic factor associated with death or lung transplantation. Journal of Hepatology 55:6, 1377-1382
CrossRef3
David Lo, Donald R. VanDevanter, Patrick Flume, Alan Smyth. (2011) Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respiratory Medicine 105, S9-S17
CrossRef4
Eric Raphael Gottlieb, Elisabeth Christine Smith, Linda Lucetta Wolfenden, Richard Mark Allman, Vin Tangpricha. (2011) Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis. The Clinical Respiratory Journal 5:4, 245-251
CrossRef5
Shuang Ji, Limin Peng, Yu Cheng, HuiChuan Lai. (2011) Quantile Regression for Doubly Censored Data. Biometricsno-no
CrossRef6
Catherine A. Sandsund, Michael Roughton, Margaret E. Hodson, Jennifer A. Pryor. (2011) Musculoskeletal techniques for clinically stable adults with cystic fibrosis: a preliminary randomised controlled trial. Physiotherapy 97:3, 209-217
CrossRef7
Chelsea Taylor, Clayton W. Commander, Joseph M. Collaco, Lisa J. Strug, Weili Li, Fred A. Wright, Aaron D. Webel, Rhonda G. Pace, Jaclyn R. Stonebraker, Kathleen Naughton, Ruslan Dorfman, Andrew Sandford, Scott M. Blackman, Yves Berthiaume, Peter Paré, Mitchell L. Drumm, Julian Zielenski, Peter Durie, Garry R. Cutting, Michael R. Knowles, Mary Corey. (2011) A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies. Pediatric Pulmonology 46:9, 857-869
CrossRef8
Roberto Buzzetti, Gianfranco Alicandro, Laura Minicucci, Sara Notarnicola, Maria Lucia Furnari, Gabriella Giordano, Vincenzina Lucidi, Enza Montemitro, Valeria Raia, Giuseppe Magazzù, Giuseppe Vieni, Serena Quattrucci, Alessandro Ferrazza, Rolando Gagliardini, Natalia Cirilli, Donatello Salvatore, Carla Colombo. (2011) Validation of a predictive survival model in Italian patients with cystic fibrosis. Journal of Cystic Fibrosis
CrossRef9
Dorota Sands, Teresa Repetto, Lieven J. Dupont, Aleksandra Korzeniewska-Eksterowicz, Paola Catastini, Susan Madge. (2011) End of life care for patients with cystic fibrosis. Journal of Cystic Fibrosis 10, S37-S44
CrossRef10
Maryl Kreider, Denis Hadjiliadis, Robert M. Kotloff. (2011) Candidate Selection, Timing of Listing, and Choice of Procedure for Lung Transplantation. Clinics in Chest Medicine 32:2, 199-211
CrossRef11
Thomas Radtke, Albert Faro, Jackson Wong, Annette Boehler, Christian Benden. (2011) Exercise testing in pediatric lung transplant candidates with cystic fibrosis. Pediatric Transplantation 15:3, 294-299
CrossRef12
Y. Cai, D. Chai, R. Wang, N. Bai, B.-B. Liang, Y. Liu. (2011) Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. Journal of Antimicrobial Chemotherapy 66:5, 968-978
CrossRef13
Christopher J van der Gast, Alan W Walker, Franziska A Stressmann, Geraint B Rogers, Paul Scott, Thomas W Daniels, Mary P Carroll, Julian Parkhill, Kenneth D Bruce. (2011) Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. The ISME Journal 5:5, 780-791
CrossRef14
Iven H. Young, Peter T.P. Bye. 2011. Gas Exchange in Disease: Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Interstitial Lung Disease. .
CrossRef15
Rodopi Stamatiou, Efrosyni Paraskeva, Maria Papagianni, Paschalis Adam Molyvdas, Apostolia Hatziefthimiou. (2011) The mitogenic effect of testosterone and 17β-estradiol on airway smooth muscle cells. Steroids 76:4, 400-408
CrossRef16
Anne Stephenson, Janet Hux, Elizabeth Tullis, Peter C. Austin, Mary Corey, Joel Ray. (2011) Higher risk of hospitalization among females with cystic fibrosis. Journal of Cystic Fibrosis 10:2, 93-99
CrossRef17
Jonathan E Spahr, Keith C Meyer. 2011. Lung Transplantation. , 205-237.
CrossRef18
Charles B. Huddleston. (2011) Pediatric Lung Transplantation. Current Treatment Options in Cardiovascular Medicine 13:1, 68-78
CrossRef19
Pamela B. Davis. (2011) Cystic Fibrosis (Role of Modifier Genes in Genotype/Phenotype Correlations). Annual Review of Pathology: Mechanisms of Disease 7:1, 110301101326014
CrossRef20
T Pincikova, K Nilsson, I E Moen, F Karpati, G Fluge, A Hollsing, P K Knudsen, A Lindblad, L Mared, T Pressler, L Hjelte. (2011) Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. European Journal of Clinical Nutrition 65:1, 102-109
CrossRef21
Marion Rowland, Charles G Gallagher, Risteard Ó'Laoide, Gerard Canny, Annemarie Broderick, Roisin Hayes, Peter Greally, Dubhfeassa Slattery, Leslie Daly, Peter Durie, Billy Bourke. (2011) Outcome in Cystic Fibrosis Liver Disease. The American Journal of Gastroenterology 106:1, 104-109
CrossRef22
Daniel H. Grossoehme, Lisa Opipari-Arrigan, Rhonda VanDyke, Sophia Thurmond, Michael Seid. (2011) Relationship of adherence determinants and parental spirituality in cystic fibrosis. Pediatric Pulmonologyn/a-n/a
CrossRef23
Gregory S. Sawicki, James E. Signorovitch, Jie Zhang, Dominick Latremouille-Viau, Markus von Wartburg, Eric Q. Wu, Lizheng Shi. (2011) Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatric Pulmonologyn/a-n/a
CrossRef24
Garry R. Cutting. (2010) Modifier genes in Mendelian disorders: the example of cystic fibrosis. Annals of the New York Academy of Sciences 1214:1, 57-69
CrossRef25
Richard Kraemer, Cindy Thamrin. (2010) Pulmonary outcome prediction for cystic fibrosis patients. Pediatric Pulmonology 45:12, 1153-1155
CrossRef26
Hanne Vebert Olesen, Tacjana Pressler, Lena Hjelte, Lena Mared, Anders Lindblad, Per Kristian Knudsen, Birger N. Laerum, Marie Johannesson. (2010) Gender differences in the Scandinavian cystic fibrosis population. Pediatric Pulmonology 45:10, 959-965
CrossRef27
Theodore G. Liou, Eric P. Elkin, David J. Pasta, Joan R. Jacobs, Michael W. Konstan, Wayne J. Morgan, Jeffrey S. Wagener. (2010) Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis 9:4, 250-256
CrossRef28
Susannah J. King, Ibolya B. Nyulasi, Boyd J.G. Strauss, Tom Kotsimbos, Michael Bailey, John W. Wilson. (2010) Fat-free mass depletion in cystic fibrosis: Associated with lung disease severity but poorly detected by body mass index. Nutrition 26:7-8, 753-759
CrossRef29
Edmund M.T. Lau, Carmel Moriarty, Robert Ogle, Peter T. Bye. (2010) Pregnancy and Cystic Fibrosis. Paediatric Respiratory Reviews 11:2, 90-94
CrossRef30
J.A. Pryor, E. Tannenbaum, S.F. Scott, J. Burgess, D. Cramer, K. Gyi, M.E. Hodson. (2010) Beyond postural drainage and percussion: Airway clearance in people with cystic fibrosis. Journal of Cystic Fibrosis 9:3, 187-192
CrossRef31
Gabriel Olveira, Casilda Olveira, Inmaculada Gaspar, Ivette Cruz, Antonio Dorado, Estela Pérez-Ruiz, Nuria Porras, Federico Soriguer. (2010) Validación de la versión española del cuestionario revisado de calidad de vida para fibrosis quística en adolescentes y adultos (CFQR 14+ Spain). Archivos de Bronconeumología 46:4, 165-175
CrossRef32
Gary M. Doherty, Paul Aurora. (2010) Update on Paediatric Lung Transplantation. Paediatric Respiratory Reviews 11:1, 54-61
CrossRef33
Ori Efrati, Irena Bylin, Eran Segal, Daphna Vilozni, Dalit Modan-Moses, Amir Vardi, Amir Szeinberg, Gideon Paret. (2010) Outcome of patients with cystic fibrosis admitted to the intensive care unit: Is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation?. Heart & Lung: The Journal of Acute and Critical Care 39:2, 153-159
CrossRef34
Anne Munck. (2010) Nutritional considerations in patients with cystic fibrosis. Expert Review of Respiratory Medicine 4:1, 47-56
CrossRef35
F.A. Millar, N.J. Simmonds, M.E. Hodson. (2009) Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005. Journal of Cystic Fibrosis 8:6, 386-391
CrossRef36
Theodore G. Liou, Richard E. Kanner. (2009) Spirometry. Clinical Reviews in Allergy & Immunology 37:3, 137-152
CrossRef37
Alexander Chuchalin, Elena Amelina, Federico Bianco. (2009) Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulmonary Pharmacology & Therapeutics 22:6, 526-532
CrossRef38
Henry J. Legere, Ross I. Palis, Tito Rodriguez Bouza, Ahmet Z. Uluer, Mariana C. Castells. (2009) A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. Journal of Cystic Fibrosis 8:6, 418-424
CrossRef39
Andrew M. Jones, Jennifer M. Helm. (2009) Emerging Treatments in Cystic Fibrosis. Drugs 69:14, 1903-1910
CrossRef40
Robert I. Ketchell, Michael Roughton, Penny Agent, Khin Gyi, Margaret E. Hodson. (2009) Predicting survival in end-stage cystic fibrosis. Respiratory Medicine 103:10, 1441-1447
CrossRef41
Paul D. Robinson, Peter Cooper, Peter Van Asperen, Dominic Fitzgerald, Hiran Selvadurai. (2009) Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. Pediatric Pulmonology 44:8, 733-742
CrossRef42
T.O. Hirche, H. Hirche, S. Jungblut, M. Stern, T.O. Wagner, B. Wiedemann. (2009) Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis. Journal of Cystic Fibrosis 8:4, 238-244
CrossRef43
Ludovic Moreau, Dominique Crenesse, Frederic Berthier, Marc Albertini. (2009) Relationship between impulse oscillometry and spirometric indices in cystic fibrosis children. Acta Paediatrica 98:6, 1019-1023
CrossRef44
Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter. (2009) Characterizing aggressiveness and predicting future progression of CF lung disease. Journal of Cystic Fibrosis 8, S15-S19
CrossRef45
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams. (2009) Early oxygen uptake recovery following exercise testing in children with chronic chest diseases. Pediatric Pulmonology 44:5, 480-488
CrossRef46
Amy N. Harrison, Warren E. Regelmann, Jacquelyn M. Zirbes, Carlos E. Milla. (2009) Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. Pediatric Pulmonology 44:4, 330-339
CrossRef47
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher. (2009) Time course and recovery of arterial blood gases during exacerbations in adults with Cystic Fibrosis. Journal of Cystic Fibrosis 8:1, 9-13
CrossRef48
Godelieve CML Page-Christiaens, Ferdinand Teding van Berkhout. 2008. The patient with cystic fibrosis. , 159-172.
CrossRef49
James E Heubi. (2008) Pancreatic enzyme-replacement therapy in CF: considerations for the USA. Expert Review of Respiratory Medicine 2:5, 589-596
CrossRef50
Rosalía Laporta, Piedad Ussetti, Gema Mora, Cristina López, David Gómez, Alicia De Pablo, M. Teresa Lázaro, M. Cruz Carreño, M. José Ferreiro. (2008) Características clínicas y funcionales antes del trasplante pulmonar. Experiencia en la Clínica Puerta de Hierro. Archivos de Bronconeumología 44:8, 424-427
CrossRef51
Michael Patrick Tuppin, Jennifer D. Paratz, Angela T. Chang, Helen E. Seale, James R. Walsh, Fiona D. Kermeeen, Keith D. McNeil, Peter M. Hopkins. (2008) Predictive Utility of the 6-Minute Walk Distance on Survival in Patients Awaiting Lung Transplantation. The Journal of Heart and Lung Transplantation 27:7, 729-734
CrossRef52
Rajeev Soni, Catherine J. Dobbin, Maree A. Milross, Iven H. Young, Peter P.T. Bye. (2008) Gas exchange in stable patients with moderate-to-severe lung disease from cystic fibrosis. Journal of Cystic Fibrosis 7:4, 285-291
CrossRef53
Ramsey R. Hachem, Elbert P. Trulock. (2008) The New Lung Allocation System and Its Impact on Waitlist Characteristics and Post-Transplant Outcomes. Seminars in Thoracic and Cardiovascular Surgery 20:2, 139-142
CrossRef54
Monique A. Malouf, Maree A. Milross, Ronald R. Grunstein, Keith Wong, Chhajed Prashant, David M.B. Jankelson, Christina L. Aboyoun, Peter T. Bye, Allan R. Glanville. (2008) Sleep-disordered Breathing Before and After Lung Transplantation. The Journal of Heart and Lung Transplantation 27:5, 540-546
CrossRef55
Julia Ley-Zaporozhan, Michael Puderbach, Hans-Ulrich Kauczor. (2008) MR for the Evaluation of Obstructive Pulmonary Disease. Magnetic Resonance Imaging Clinics of North America 16:2, 291-308
CrossRef56
Stuart C. Sweet, Paul Aurora, Christian Benden, Jackson Y. Wong, Samuel B. Goldfarb, Okan Elidemir, Marlyn S. Woo, George B. Mallory, . (2008) Lung transplantation and survival in children with cystic fibrosis: Solid statistics - Flawed interpretation. Pediatric Transplantation 12:2, 129-136
CrossRef57
Anastasia Oikonomou, John Tsanakas, Elpis Hatziagorou, Fotios Kirvassilis, Stavros Efremidis, Panos Prassopoulos. (2008) High resolution computed tomography of the chest in cystic fibrosis (CF): is simplification of scoring systems feasible?. European Radiology 18:3, 538-547
CrossRef58
Alex G. Cuenca, Elizabeth A. Beierle. (2008) Pulmonary surgery in cystic fibrosis. Seminars in Pediatric Surgery 17:1, 60-65
CrossRef59
Iwona Stelmach, Aleksandra Korzeniewska, Włodzimierz Stelmach. (2008) Long-Term Benefits of Inhaled Tobramycin in Children with Cystic Fibrosis: First Clinical Observations from Poland. Respiration 75:2, 178-181
CrossRef60
Liou, Theodore G., Adler, Frederick R., Cox, David R., Cahill, Barbara C., . (2007) Lung Transplantation and Survival in Children with Cystic Fibrosis. New England Journal of Medicine 357:21, 2143-2152
Full Text61
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer. (2007) Lung transplantation for cystic fibrosis: Current concepts and one center's experience. Journal of Cystic Fibrosis 6:5, 334-350
CrossRef62
J.M. Courtney, J. Bradley, J. Mccaughan, T.M. O'connor, C. Shortt, C.P. Bredin, I. Bradbury, J.S. Elborn. (2007) Predictors of mortality in adults with cystic fibrosis. Pediatric Pulmonology 42:6, 525-532
CrossRef63
Carlos E. Milla. (2007) Nutrition and Lung Disease in Cystic Fibrosis. Clinics in Chest Medicine 28:2, 319-330
CrossRef64
Hilary J. Goldberg, Aaron Deykin. (2007) Advances in Lung Transplantation for Patients Who Have Cystic Fibrosis. Clinics in Chest Medicine 28:2, 445-457
CrossRef65
B Wiedemann, K D Paul, M Stern, T O Wagner, T O Hirche. (2007) Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis. European Journal of Clinical Nutrition 61:6, 759-768
CrossRef66
Ori Efrati, Mordechai R. Kremer, Asher Barak, Arie Augarten, Nira Reichart, Amir Vardi, Dalit Modan-Moses. (2007) Improved Survival Following Lung Transplantation with Long-Term Use Of Bilevel Positive Pressure Ventilation in Cystic Fibrosis. Lung 185:2, 73-79
CrossRef67
R. Pellegrino, G. Viegi, V. Brusasco, R.O. Crapo, F. Burgos, R. Casaburi, A. Coates, C.P.M. Van Der Grinten, P. Gustafsson, J. Hankinson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, M.R. Miller, D. Navajas, O.F. Pedersen, Et J. Wanger. (2007) Stratégies d’interprétation des explorations fonctionnelles respiratoires. Revue des Maladies Respiratoires 24:3, 83-108
CrossRef68
Damian G. Downey, S. Lorraine Martin, Martin Dempster, John E. Moore, Mary T. Keogan, Barry Starcher, Julia Edgar, Diana Bilton, J. Stuart Elborn. (2007) The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatric Pulmonology 42:3, 216-220
CrossRef69
Arnon Elizur, Stuart C. Sweet, Charles B. Huddleston, Sanjiv K. Gandhi, Sarah E. Boslaugh, Cadence A. Kuklinski, Albert Faro. (2007) Pre-transplant Mechanical Ventilation Increases Short-term Morbidity and Mortality in Pediatric Patients With Cystic Fibrosis. The Journal of Heart and Lung Transplantation 26:2, 127-131
CrossRef70
Ranjan Suri, Chris Metcalfe, Colin Wallis, Andrew Bush. (2007) Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine 101:2, 254-260
CrossRef71
Alexander Chuchalin, Eszter Csisz??r, K??lm??n Gyurkovics, Maria Trawi??ska Bartnicka, Dorota Sands, Nikolai Kapranov, Guido Varoli, Pier Alessandro Monici Preti, Henryk Mazurek. (2007) A Formulation of Aerosolized Tobramycin (Bramitob??) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection. Pediatric Drugs 9:Supplement 1, 21-31
CrossRef72
David Adeboyeku, Sandra Scott, Margaret E. Hodson. (2006) Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. Journal of Cystic Fibrosis 5:4, 261-263
CrossRef73
Theodore G Liou, Marlyn S Woo, Barbara C Cahill. (2006) Lung transplantation for cystic fibrosis. Current Opinion in Pulmonary Medicine 12:6, 459-463
CrossRef74
R. Laporta Hernández, C. López Gacía-Gallo, G. Mora Ortega, A. Trisán Alonso. (2006) Trasplante de pulmón. Medicine - Programa de Formación Médica Continuada Acreditado 9:67, 4324-4330
CrossRef75
Garry R Cutting. (2006) Cystic Fibrosis: Using genetic association to identify modifiers of disease variability in cystic fibrosis. European Journal of Human Genetics 14:8, 890-891
CrossRef76
Gaudenz M. Hafen, Sarath C. Ranganathan, Colin F. Robertson, Philip J. Robinson. (2006) Clinical scoring systems in cystic fibrosis. Pediatric Pulmonology 41:7, 602-617
CrossRef77
Jonathan B. Orens, Marc Estenne, Selim Arcasoy, John V. Conte, Paul Corris, Jim J. Egan, Thomas Egan, Shaf Keshavjee, Christiane Knoop, Robert Kotloff, Fernando J. Martinez, Steven Nathan, Scott Palmer, Alec Patterson, Lianne Singer, Gregory Snell, Sean Studer, J.L. Vachiery, Allan R. Glanville. (2006) International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update—A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. The Journal of Heart and Lung Transplantation 25:7, 745-755
CrossRef78
Clement L. Ren, Justin L. Brucker, Amy K. Rovitelli, Kimberly A. Bordeaux. (2006) Changes in lung function measured by spirometry and the forced oscillation technique in cystic fibrosis patients undergoing treatment for respiratory tract exacerbation. Pediatric Pulmonology 41:4, 345-349
CrossRef79
Jonathan McCormick, Erika J. Sims, Anil Mehta. (2006) Delayed diagnosis of females with respiratory presentation of cystic fibrosis did not segregate with poorer clinical outcome. Journal of Clinical Epidemiology 59:3, 315-322
CrossRef80
Lynne Maxwell, Salvatore R. Goodwin, Thomas J. Mancuso, Victor C. Baum, Aaron L. Zuckerberg, Philip G. Morgan, Etsuro K. Motoyama, Peter J. Davis. 2006. Systemic Disorders in Infants and Children. , 1032-1109.
CrossRef81
Jonas Schrey??gg, Helge Hollmeyer, Miriam Bluemel, Doris Staab, Reinhard Busse. (2006) Hospitalisation Costs of Cystic Fibrosis. PharmacoEconomics 24:10, 999-1009
CrossRef82
Lisa Lang, Alistair J.A. Duff, Keith G. Brownlee. (2005) Introducing the need for lung transplantation in children with cystic fibrosis: Parental experiences. Journal of Cystic Fibrosis 4:4, 259-262
CrossRef83
Drumm, Mitchell L., Konstan, Michael W., Schluchter, Mark D., Handler, Allison, Pace, Rhonda, Zou, Fei, Zariwala, Maimoona, Fargo, David, Xu, Airong, Dunn, John M., Darrah, Rebecca J., Dorfman, Ruslan, Sandford, Andrew J., Corey, Mary, Zielenski, Julian, Durie, Peter, Goddard, Katrina, Yankaskas, James R., Wright, Fred A., Knowles, Michael R., . (2005) Genetic Modifiers of Lung Disease in Cystic Fibrosis. New England Journal of Medicine 353:14, 1443-1453
Full Text84
Virginia A. Stallings, Jean L. Tomezsko, Joan I. Schall, Maria R. Mascarenhas, Nicolas Stettler, Thomas F. Scanlin, Babette S. Zemel. (2005) Adolescent development and energy expenditure in females with cystic fibrosis. Clinical Nutrition 24:5, 737-745
CrossRef85
Paul Pianosi, John LeBlanc, Anthony Almudevar. (2005) Relationship between FEV1 and peak oxygen uptake in children with cystic fibrosis. Pediatric Pulmonology 40:4, 324-329
CrossRef86
R. Canton, N. Cobos, J. de Gracia, F. Baquero, J. Honorato, S. Gartner, A. Alvarez, A. Salcedo, A. Oliver, E. Garcia-Quetglas, . (2005) Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection 11:9, 690-703
CrossRef87
Steven Nathan. (2005) Lung transplant candidate selection and clinical outcomes: strategies for improvement in prioritization. Current Opinion in Organ Transplantation 10:3, 216-220
CrossRef88
Susan S. Baker, Drucy Borowitz, Robert D. Baker. (2005) Pancreatic exocrine function in patients with cystic fibrosis. Current Gastroenterology Reports 7:3, 227-233
CrossRef89
A. de Pablo, S. López, P. Ussetti, M.C. Carreño, R. Laporta, C. López García-Gallo, M.J. Ferreiro. (2005) Trasplante pulmonar en enfermedades supurativas. Archivos de Bronconeumología 41:5, 255-259
CrossRef90
Eitan Kerem, Steven Conway, Stuart Elborn, Harry Heijerman. (2005) Standards of care for patients with cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 4:1, 7-26
CrossRef91
R. Cantón, N. Cobos, J. de Gracia, F. Baquero, J. Honorato, S. Gartner, A. Álvarez, A. Salcedo, A. Oliver, E. García-Quetglas. (2005) Tratamiento antimicrobiano frente a la colonización pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quística. Archivos de Bronconeumología 41, 1-25
CrossRef92
Catherine J. Dobbin, Maree A. Milross, Amanda J. Piper, Colin Sullivan, Ronald R. Grunstein, Peter T.P. Bye. (2004) Sequential use of oxygen and bi-level ventilation for respiratory failure in cystic fibrosis. Journal of Cystic Fibrosis 3:4, 237-242
CrossRef93
Carlos E Milla. (2004) Association of nutritional status and pulmonary function in children with cystic fibrosis. Current Opinion in Pulmonary Medicine 10:6, 505-509
CrossRef94
Maree A. Milross, Amanda J. Piper, Catherine J. Dobbin, Peter T.P. Bye, Ronald R. Grunstein. (2004) Sleep disordered breathing in cystic fibrosis. Sleep Medicine Reviews 8:4, 295-308
CrossRef95
Metehan Ozen, Haluk Cokugras, Naile Ozen, Yildiz Camcioglu, Necla Akcakaya. (2004) Relation between serum Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 levels, clinical status and growth parameters in prepubertal cystic fibrosis patients. Pediatrics International 46:4, 429-435
CrossRef96
Padmaja Subbarao, Patrick Lebecque, Mary Corey, Allan L. Coates. (2004) Comparison of spirometric reference values. Pediatric Pulmonology 37:6, 515-522
CrossRef97
Clemens Aigner, Peter Jaksch, Gernot Seebacher, Samy Mazhar, Wilfried Wisser, Walter Klepetko. (2004) Cystic fibrosis and lung transplantation — Determination of the survival benefit. Wiener Klinische Wochenschrift 116:9-10, 318-321
CrossRef98
Hima Vedam, Carmel Moriarty, Paul J. Torzillo, David McWilliam, Peter T.P. Bye. (2004) Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. Journal of Cystic Fibrosis 3:1, 8-14
CrossRef99
Paul Aurora. (2004) When should children be referred for lung or heart-lung transplantation?. Pediatric Pulmonology 37:S26, 116-118
CrossRef100
Gerrit S Zijlstra, Cornelis Boersma, Henderik W Frijlink, Maarten J Postma. (2004) Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 49-59
CrossRef101
C. J. Dobbin, P. T. P. Bye. (2003) Adults with cystic fibrosis: meeting the challenge!. Internal Medicine Journal 33:12, 593-597
CrossRef102
S SWEET. (2003) Pediatric lung transplantation: update 2003. Pediatric Clinics of North America 50:6, 1393-1417
CrossRef103
Richard Iles, Julia Legh-Smith, Michael Drummond, Andrew Prevost, Sarah Vowler. (2003) Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. Journal of Cystic Fibrosis 2:3, 120-128
CrossRef104
Alan R Smyth, Sarah Walters, Alan R Smyth. 2003. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. .
CrossRef105
Anthony De Soyza, Linda Archer, J Wardle, Gareth Parry, John H Dark, Kate Gould, Paul A Corris. (2003) Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. The Journal of Heart and Lung Transplantation 22:7, 764-769
CrossRef106
Omar M. Pirzada, Jean McGaw, Christopher J. Taylor, Mark L. Everard. (2003) Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. Journal of Cystic Fibrosis 2:2, 69-71
CrossRef107
Edward F McKone, Scott S Emerson, Karen L Edwards, Moira L Aitken. (2003) Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. The Lancet 361:9370, 1671-1676
CrossRef108
Kristina Rüter, Doris Staab, Klaus Magdorf, Susanne Bisson, Ulrich Wahn, Karl Paul. (2003) The 12-min walk test as an assessment criterion for lung transplantation in subjects with cystic fibrosis. Journal of Cystic Fibrosis 2:1, 8-13
CrossRef109
Felix Ratjen, Gerd Döring. (2003) Cystic fibrosis. The Lancet 361:9358, 681-689
CrossRef110
Carla Colombo, Pier Maria Battezzati, Andrea Crosignani, Alberto Morabito, Diana Costantini, Rita Padoan, Annamaria Giunta. (2002) Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 36:6, 1374-1382
CrossRef111
Theodore G. Liou, Barbara C. Cahill, Frederick R. Adler, Bruce C. Marshall. (2002) Selection of patients with cystic fibrosis for lung transplantation. Current Opinion in Pulmonary Medicine 8:6, 535-541
CrossRef112
William S. Krimsky, H. Worth Parker. (2002) Update: epidemiology of cystic fibrosis. Current Opinion in Pulmonary Medicine 8:6, 552-553
CrossRef113
Ashby M. Jordan, Sangeeta M. Bhorade. (2002) Lung transplantation for cystic fibrosis. Current Opinion in Organ Transplantation 7:3, 254-259
CrossRef114
Drucy Borowitz, Robert D. Baker, Virginia Stallings. (2002) Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition 35:3, 246-259
CrossRef115
A Smyth. (2002) Treatment of children with cystic fibrosis: central, local or both?. Acta Paediatrica 91:9, 894-895
CrossRef116
Luca A Vricella, John M Karamichalis, Shahzad Ahmad, Robert C Robbins, Richard I Whyte, Bruce A Reitz. (2002) Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the stanford experience. The Annals of Thoracic Surgery 74:1, 13-18
CrossRef117
Maree A Milross, Amanda J Piper, Mark Norman, Catherine J Dobbin, Ronald R Grunstein, Colin E Sullivan, Peter T.P Bye. (2002) Subjective sleep quality in cystic fibrosis. Sleep Medicine 3:3, 205-212
CrossRef118
Michael L Stanchina, Kelan G Tantisira, Suzanne L Aquino, John C Wain, Leo C Ginns. (2002) Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. The Journal of Heart and Lung Transplantation 21:2, 217-225
CrossRef119
Gerald T. O'Connor, Hebe B. Quinton, Richard Kahn, Priscilla Robichaud, Joanne Maddock, Thomas Lever, Mark Detzer, John G. Brooks, . (2002) Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatric Pulmonology 33:2, 99-105
CrossRef120
Refika Hamutcu, Marlyn S. Woo. (2001) Advanced cystic fibrosis lung disease in children. Current Opinion in Pulmonary Medicine 7:6, 448-453
CrossRef121
(2001) Is FEV 1 < 30% an indicator for lung transplantation in cystic fibrosis patients?. Pediatric Transplantation 5:5, 317-319
CrossRef122
Arie Augarten, Hannah Akons, Micha Aviram, Lea Bentur, Hannah Blau, Elie Picard, Joseph Rivlin, Mervyn S. Miller, Daniel Katznelson, Amir Szeinberg, Haim Shmilovich, Gideon Paret, Joseph Laufer, Yaacov Yahav. (2001) Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatric Transplantation 5:5, 339-342
CrossRef123
Mary Jayne Kennedy. (2001) Inflammation and Cystic Fibrosis Pulmonary Disease. Pharmacotherapy 21:5, 593-603
CrossRef124
M Furuya. (2001) Efficacy of Human Recombinant DNase in Pediatric Patients with Cystic Fibrosis. Archives of Medical Research 32:1, 30-34
CrossRef125
Jeffrey A. Johnson, Melinda Connolly, Peter Zuberbuhler, Neil E. Brown. (2000) Health-Related Quality of Life for Adults with Cystic Fibrosis: A Regression Approach to Assessing the Impact of Recombinant Human DNase. Pharmacotherapy 20:10, 1167-1174
CrossRef126
Walter Robinson, David A. Waltz. (2000) FEV1 as a guide to lung transplant referral in young patients with cystic fibrosis. Pediatric Pulmonology 30:3, 198-202
CrossRef127
P. Aurora, I.M.Balfour Lynn. (2000) Lung transplantation and end of life issues in cystic fibrosis. Paediatric Respiratory Reviews 1:2, 114-120
CrossRef128
Walter Robinson. (2000) Palliative Care in Cystic Fibrosis. Journal of Palliative Medicine 3:2, 187-192
CrossRef129
Federico Venuta, Erino A. Rendina, Giorgio Della Rocca, Tiziano De Giacomo, Francesco Pugliese, Anna Maria Ciccone, Carmine D. Vizza, Giorgio Furio Coloni, G.Alexander Patterson. (2000) Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. The Journal of Thoracic and Cardiovascular Surgery 119:4, 682-689
CrossRef130
Lai, Hui-Chuan, FitzSimmons, Stacey C., Allen, David B., Kosorok, Michael R., Rosenstein, Beryl J., Campbell, Preston W., Farrell, Philip M., . (2000) Risk of Persistent Growth Impairment after Alternate-Day Prednisone Treatment in Children with Cystic Fibrosis. New England Journal of Medicine 342:12, 851-859
Full Text131
F. Christopher, D. Chase, K. Stein, R. Milne. (1999) rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. Journal of Clinical Pharmacy and Therapeutics 24:6, 415-426
CrossRef132
Dana S. Hardin, Antoinette Moran. (1999) DIABETES MELLITUS IN CYSTIC FIBROSIS. Endocrinology & Metabolism Clinics of North America 28:4, 787-800
CrossRef133
M. H
usler, E. Franke, G. Wendt, H. Kentrup, H. D
CrossRef134
P Aurora, B Whitehead, A Wade, J Bowyer, P Whitmore, PG Rees, VT Tsang, MJ Elliott, M de Leval. (1999) Lung transplantation and life extension in children with cystic fibrosis. The Lancet 354:9190, 1591-1593
CrossRef135
Michael W. Konstan, Steven M. Butler, Daniel V. Schidlow, Wayne J. Morgan, Joanne R. Julius, . (1999) Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Pediatric Pulmonology 28:4, 248-254
CrossRef136
Michael W. Konstan, Steven M. Butler, Daniel V. Schidlow, Wayne J. Morgan, Joanne R. Julius, . (1999) Patterns of medical practice in cystic fibrosis: Part I. Evaluation and monitoring of health status of patients. Pediatric Pulmonology 28:4, 242-247
CrossRef137
Jeffrey A. Johnson, Melinda A. Connolly, Philip Jacobs, Mark Montgomery, Neil E. Brown, Peter Zuberbuhler. (1999) Cost of Care for Individuals with Cystic Fibrosis: A Regression Approach to Determining the Impact of Recombinant Human DNase. Pharmacotherapy 19:10, 1159-1166
CrossRef138
Omar A Minai, Janet R Maurer, Steven Kesten. (1999) Comorbidities in end-stage lung disease. The Journal of Heart and Lung Transplantation 18:9, 891-903
CrossRef139
LC Lands, C Dezateux, A Crighton, Larry Lands. 1999. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. .
CrossRef140
Gerald O’Brien, Gerard J. Criner. (1999) Mechanical ventilation as a bridge to lung transplantation. The Journal of Heart and Lung Transplantation 18:3, 255-265
CrossRef141
Ramsey, Bonnie W., Pepe, Margaret S., Quan, Joanne M., Otto, Kelly L., Montgomery, A. Bruce, Williams-Warren, Judy, Vasiljev-K, Michael, Borowitz, Drucy, Bowman, C. Michael, Marshall, Bruce C., Marshall, Susan, Smith, Arnold L., . (1999) Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. New England Journal of Medicine 340:1, 23-30
Full Text142
(1998) Symposium Session Summaries: Sessions 13.4 to 18.4. Pediatric Pulmonology 26:S17, 146-175
CrossRef143
Jonathan B. Zuckerman, Robert M. Kotloff. (1998) LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS. Clinics in Chest Medicine 19:3, 535-554
CrossRef144
Thomas M Egan, Frank C Detterbeck, Michael R Mill, Kristi K Gott, Jean B Rea, Judy McSweeney, Robert M Aris, Linda J Paradowski. (1998) Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group. The Annals of Thoracic Surgery 66:2, 337-345
CrossRef145
Helle Krogh Johansen, Thomas A. Kovesi, Christian Koch, Mary Corey, Niels Høiby, Henry Levison. (1998) Pseudomonas aeruginosa andBurkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatric Pulmonology 26:2, 89-96
CrossRef146
E. CLINTON LAWRENCE. (1998) Ethical Issues in Lung Transplantation. The American Journal of the Medical Sciences 315:3, 142-145
CrossRef147
Hui-Chuan Lai, Michael R. Kosorok, Sherie A. Sondel, Shu-Tien Chen, Stacey C. FitzSimmons, Christopher G. Green, Guanghong Shen, Sarah Walker, Philip M. Farrell. (1998) Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: Evaluation of various criteria used to identify malnutrition. The Journal of Pediatrics 132:3, 478-485
CrossRef148
A.T. Hill, F.P. Edenborough, R.M. Cayton, D.E. Stableforth. (1998) Long-term nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure (1991–1996). Respiratory Medicine 92:3, 523-526
CrossRef149
Eric N. Mendeloff, Charles B. Huddleston, George B. Mallory, Elbert P. Trulock, Alan H. Cohen, Stuart C. Sweet, John Lynch, Sudhir Sundaresan, Joel D. Cooper, G.Alec Patterson. (1998) Pediatric And Adult Lung Transplantation For Cystic Fibrosis. The Journal of Thoracic and Cardiovascular Surgery 115:2, 404-414
CrossRef150
Jeffrey D. Edelman, Robert M. Kotloff. (1997) LUNG TRANSPLANTATION. Clinics in Chest Medicine 18:3, 627-644
CrossRef151
Scott Manaker, Gregory Tino. (1997) NATURAL HISTORY AND PROGNOSIS OF ADVANCED LUNG DISEASE. Clinics in Chest Medicine 18:3, 435-455
CrossRef152
Cecilia M. Smith. (1997) PATIENT SELECTION, EVALUATION, AND PREOPERATIVE MANAGEMENT FOR LUNG TRANSPLANT CANDIDATES. Clinics in Chest Medicine 18:2, 183-197
CrossRef153
George B. Mallory, Alan H. Cohen. (1997) DONOR CONSIDERATIONS IN LIVING-RELATED DONOR LUNG TRANSPLANTATION. Clinics in Chest Medicine 18:2, 239-244
CrossRef154
Paul C. Stillwell, George B. Mallory. (1997) PEDIATRIC LUNG TRANSPLANTATION. Clinics in Chest Medicine 18:2, 405-414
CrossRef155
Ruth J. McDonald, Micheal J. Lukason, Otto G. Raabe, Don R. Canfield, Elizabeth A. Burr, Johanne M. Kaplan, Samuel C. Wadsworth, Judith A. St. George. (1997) Safety of Airway Gene Transfer with Ad2/CFTR2: Aerosol Administration in the Nonhuman Primate. Human Gene Therapy 8:4, 411-422
CrossRef156
S. M. Sawyer, C. F. Robertson, G. Bowes. (1997) Cystic fibrosis: a changing clinical perspective. Australian and New Zealand Journal of Medicine 27:1, 6-11
CrossRef157
PAMELA B. DAVIS, PAMELA J. BYARD, MICHAEL W. KONSTAN. (1997) Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis. Pediatric Research 41:2, 161-165
CrossRef158
Blakeslee E. Noyes, Geoffrey Kurland, David M. Orenstein. (1997) Lung and heart-lung transplantation in children. Pediatric Pulmonology 23:1, 39-48
CrossRef159
Birgitte Frederiksen, Susanne Lanng, Christian Koch, Niels Hølby. (1996) Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment. Pediatric Pulmonology 21:3, 153-158
CrossRef160
Gerard J. Canny. (1996) Hypertonic saline in cystic fibrosis. Pediatric Pulmonology 21:2, 73-74
CrossRef161
P.L. Shah, S.F. Scott, D.M. Geddes, M.E. Hodson. (1995) Two years experience with recombinant Human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respiratory Medicine 89:7, 499-502
CrossRef162
Gan, King-HanVeeze, Henk J.van den Ouweland, AnsHalley, DickyScheffer, Hansvan der Hout, AnnemiekeOverbeek, Shelley E.de Jongste, Johan C.Bakker, WillemHeijerman, Harry. (1995) A Cystic Fibrosis Mutation Associated with Mild Lung Disease. New England Journal of Medicine 333:2, 95-99
Full Text163
T. S. WALSH, C. H. YOUNG. (1995) Anaesthesia and cystic fibrosis. Anaesthesia 50:7, 614-622
CrossRef164
David Spencer, Peter Weller. (1995) Dornase-alfa for cystic fibrosis. The Lancet 345:8960, 1307
CrossRef165
Konstan, Michael W., Byard, Pamela J., Hoppel, Charles L., Davis, Pamela B., . (1995) Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis. New England Journal of Medicine 332:13, 848-854
Full Text166
Gregory D. Trachietis, Simon R. Knight, Mindy Hann, Mary S. Pohl, G.Alexander Patterson, Joel D. Cooper, Elbert P. Trulock. (1994) Respiratory responses to CO2 rebreathing in lung transplant recipients. The Annals of Thoracic Surgery 58:6, 1709-1717
CrossRef167
Davis, Pamela B., . (1994) Evolution of Therapy for Cystic Fibrosis. New England Journal of Medicine 331:10, 672-673
Full Text168
M. R. Bye, J. M. Ewig, L. M. Quittell. (1994) Cystic fibrosis. Lung 172:5, 251-270
CrossRef169
Michel Roulet. (1994) Protein-energy malnutrition in cystic fibrosis patients. Acta Paediatrica 83:s395, 43-48
CrossRef170
G. Borgo, P. Gasparini, A. Bonizzato, G. Cabrini, G. Mastella, P. F. Pignatti. (1993) Cystic fibrosis: The ΔF508 mutation does not lead to an exceptionally severe phenotype. A cohort study. European Journal of Pediatrics 152:12, 1006-1011
CrossRef171
A.K. Webb, M. Dodd, J. Abbott, J. Maddison. (1993) Adult cystic fibrosis: Current issues in a regional unit. Respiratory Medicine 87:1, 9-15
CrossRef172
(1992) Prognosis in Cystic Fibrosis. New England Journal of Medicine 327:17, 1244-1245
Full Text
- Letters
